Newly Defined Breast Cancer Targets Expand TNBC Treatment Options

Kevin Kalinsky, MD, MS, discusses genetic sequencing in triple-negative breast cancer, the significance of breast cancer tumor board discussions for informing further research and optimizing patient care, and how future directions in breast cancer treatment are building off the current benefits of drugs classes like antibody-drug conjugates.

Related Keywords

Miami ,Florida ,United States ,Emory University ,Georgia ,Kevin Kalinsky ,Department Of Hematology ,Breast Cancer Research ,Oncology At Emory University School Of Medicine ,Glenn Family Breast Center ,Annual Miami Breast Cancer ,Medical Oncology ,Emory University School ,Rand Glenn Family Chair ,Breast Medical Oncology ,Winship Cancer Institute ,D ,Us ,Patients With Triple Negative Breast Cancer ,Genetic Sequencing In Tnbc ,Breast Cancer Tumor Board Discussions ,Future Directions In Breast Cancer Treatment ,Destiny Breast04 Trial ,Nct03734029 ,Ascent Trial ,Nct02574455 ,Emory University School Of Medicine ,Winship Cancer Institute Of Emory University ,